VBIV vs. GLTO, AYTU, SLGL, INDP, GLYC, COCP, NERV, TLPH, KALA, and NRBO
Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include Galecto (GLTO), Aytu BioPharma (AYTU), Sol-Gel Technologies (SLGL), Indaptus Therapeutics (INDP), GlycoMimetics (GLYC), Cocrystal Pharma (COCP), Minerva Neurosciences (NERV), Talphera (TLPH), KALA BIO (KALA), and NeuroBo Pharmaceuticals (NRBO). These companies are all part of the "pharmaceutical preparations" industry.
VBI Vaccines (NASDAQ:VBIV) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.
In the previous week, VBI Vaccines had 3 more articles in the media than Galecto. MarketBeat recorded 3 mentions for VBI Vaccines and 0 mentions for Galecto. Galecto's average media sentiment score of 0.00 beat VBI Vaccines' score of -0.87 indicating that Galecto is being referred to more favorably in the news media.
Galecto has lower revenue, but higher earnings than VBI Vaccines.
Galecto has a net margin of 0.00% compared to VBI Vaccines' net margin of -881.79%. Galecto's return on equity of -87.11% beat VBI Vaccines' return on equity.
VBI Vaccines has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Galecto has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
12.3% of VBI Vaccines shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 10.4% of VBI Vaccines shares are held by company insiders. Comparatively, 12.1% of Galecto shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
VBI Vaccines received 470 more outperform votes than Galecto when rated by MarketBeat users. Likewise, 74.63% of users gave VBI Vaccines an outperform vote while only 58.82% of users gave Galecto an outperform vote.
Galecto has a consensus price target of $5.33, indicating a potential upside of 758.69%. Given Galecto's higher probable upside, analysts clearly believe Galecto is more favorable than VBI Vaccines.
Summary
Galecto beats VBI Vaccines on 8 of the 14 factors compared between the two stocks.
Get VBI Vaccines News Delivered to You Automatically
Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VBI Vaccines Competitors List
Related Companies and Tools
